BioVie Inc.

13.90-1.88-11.91%Vol 100.46K1Y Perf 231.19%
Apr 13th, 2021 16:00 DELAYED
BID13.89 ASK14.02
Open15.67 Previous Close15.78
Pre-Market- After-Market-
 - -  - -%
Target Price
47.00 
Analyst Rating
— — 0.00
Potential %
238.13 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap193.43M 
Earnings Rating
Price Range Ratio 52W %
24.41 
Earnings Date
-

Today's Price Range

13.6916.00

52W Range

3.5046.10

5 Year PE Ratio Range

-24.20-6.30

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-14.57%
1 Month
-31.86%
3 Months
-53.57%
6 Months
31.75%
1 Year
231.19%
3 Years
270.67%
5 Years
85.33%
10 Years
-

TickerPriceChg.Chg.%
BIVI13.90-1.8800-11.91
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.12-0.22-83.33
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume100.46K
Shares Outstanding13.92M
Trades Count1.22K
Dollar Volume3.60M
Avg. Volume100.36K
Avg. Weekly Volume46.75K
Avg. Monthly Volume50.29K
Avg. Quarterly Volume101.56K

BioVie Inc. (NASDAQ: BIVI) stock closed at 13.9 per share at the end of the most recent trading day (a -11.91% change compared to the prior day closing price) with a volume of 100.51K shares and market capitalization of 193.43M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 4 people. BioVie Inc. CEO is Terren S. Peizer.

The one-year performance of BioVie Inc. stock is 231.19%, while year-to-date (YTD) performance is -19.75%. BIVI stock has a five-year performance of 85.33%. Its 52-week range is between 3.5 and 46.1, which gives BIVI stock a 52-week price range ratio of 24.41%

BioVie Inc. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 17.90, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -871.47%, a ROC of -1 201.49% and a ROE of -1 248.24%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from BioVie Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. BioVie Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for BioVie Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for BioVie Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioVie Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioVie Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 25.45, ATR14 : 4.83, CCI20 : -171.13, Chaikin Money Flow : -0.18, MACD : -4.76, Money Flow Index : 21.72, ROC : -20.80, RSI : 39.19, STOCH (14,3) : 2.81, STOCH RSI : 0.76, UO : 34.18, Williams %R : -97.19), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioVie Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

BioVie Inc.

BioVie Inc is active in the healthcare domain in the United States. The company is a development stage enterprise engaged in the discovery, development, and commercialization of a therapy targeting ascites due to liver cirrhosis. Its therapy BIV201 is based on a drug that is approved in about 40 countries to treat related complications of liver cirrhosis. BioVie is developing BIV201 for alleviating the portal hypertension and correcting splanchnic vasodilation, thereby increasing effective blood volume and reducing the signals to the kidneys to retain excess salt and water.

CEO: Terren S. Peizer

Telephone: +1 312 283-5793

Address: 2120 Colorado Avenue, Santa Monica 90404, CA, US

Number of employees: 4

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

80%20%

Bearish Bullish

75%25%

News

Stocktwits